


TRANSMITTAL LETTER
(General - Patent Pending)



Docket No.
2290.00061

In Re Application Of: SARA LAVI

Serial No.
09/029,479

Filing Date
10/21/98

Examiner
WOITACH, J.

Group Art Unit
1632

Title: MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE 2C-PP2CALPHA - EXPRESSION IN
TUMOR CELLS FOR CANCER THERAPY, PREVENTION AND DETECTION

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

SUBMISSION OF SEQUENCE LISTING STATEMENT; STATEMENT THAT SEQUENCE LISTING AND
COMPUTER READABLE COPY ARE THE SAME; HARD COPY OF SEQUENCE LISTING; COPY OF
SEQUENCE LISTING ON DISKETTE; TRANSMITTAL LETTER; CHECK #7916 IN THE AMOUNT OF
\$190.00 AND POSTCARD.

in the above identified application.

No additional fee is required.
 A check in the amount of \$190.00 is attached.
 The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 11-1449
as described below. A duplicate copy of this sheet is enclosed.
 Charge the amount of
 Credit any overpayment.
 Charge any additional fee required.

RECEIVED
FEB 25 2000
1600 MAIL ROOM

FEB 22 2000
TECH CENTER 1600/2900

Signature

Dated: February 9, 2000

AMY E. RINALDO
KOHN & ASSOCIATES
30500 Northwestern Hwy., Suite 410
Farmington Hills, Michigan 48334-3179
(248) 539-5050
(248) 539-5055 FAX

02/17/2000 TTRW1 00000030 09029479

01 FC:216 190.00 OP

CC:

I certify that this document and fee is being deposited on
with the U.S. Postal Service as
first class mail under 37 C.F.R. 1.8 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C.
20231.

Marie M. DeWitt
Signature of Person Mailing Correspondence

Marie M. DeWitt

Typed or Printed Name of Person Mailing Correspondence



See List 1-2-00
UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/029,479	10/21/98	LAVI	2290.00061 (1)

ILENE N MONTGOMERY
KOHN & ASSOCIATES
30500 NORTHWESTERN HIGHWAY
STE 410
FARMINGTON HILLS MI 48334

HM32/1202

EXAMINER

WOITACH, J

ART UNIT
1632

PAPER NUMBER



DATE MAILED: 12/02/99

Please find below and/or attached an Office communication concerning this application or proceeding.


Commissioner of Patents and Trademarks

RECEIVED
FEB 25 2000
TC 1600 MAIL ROOM



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/029,479	10/21/98	Lavi, S., et. al.	2290.00061(tau)



EXAMINER	
Joseph T. Woitach	
ART UNIT	PAPER NUMBER
1632	7

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Joseph T. Woitach Art Unit 1632, whose telephone number is (703) 305-3732.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

BRUCE R. CAMPBELL
PRIMARY EXAMINER
GROUP 1800

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

